Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $192.24 USD
Change Today +1.86 / 0.98%
Volume 392.2K
JAZZ On Other Exchanges
As of 8:10 PM 07/31/15 All times are local (Market data is delayed by at least 15 minutes).

jazz pharmaceuticals plc (JAZZ) Snapshot

Previous Close
Day High
Day Low
52 Week High
07/31/15 - $194.73
52 Week Low
08/8/14 - $131.69
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

jazz pharmaceuticals plc (JAZZ) Related Businessweek News

No Related Businessweek News Found

jazz pharmaceuticals plc (JAZZ) Details

Jazz Pharmaceuticals Public Limited Company, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for various medical needs in the United States, Europe, and internationally. Its products comprise Xyrem, an oral solution for the treatment of cataplexy and excessive daytime sleepiness (EDS) in patients with narcolepsy; Erwinaze to treat acute lymphoblastic leukemia (ALL); Defitelio for the treatment and prevention of severe hepatic veno-occlusive disease, a potentially life-threatening complication of hematopoietic stem cell transplantation; and Prialt, an intrathecally administered infusion of ziconotide for the management of severe chronic pain. The company also develops JZP-110, an investigational compound, which is in clinical development for the treatment of EDS in patients with narcolepsy; and JZP-386, a deuterium-modified analog of sodium oxybate that is in phase I clinical trail for use in patients with narcolepsy. In addition, it develops products in the areas of hematology and oncology, such as JZP-416, which has completed phase I clinical trial for the treatment of patients with ALL who are hypersensitive to E. coli-derived asparaginase; and Leukotac, an anti-CD25 monoclonal antibody that is in phase III clinical trials for the treatment of steroid-refractory acute graft vs. host disease. The company is headquartered in Dublin, Ireland.

835 Employees
Last Reported Date: 05/7/15

jazz pharmaceuticals plc (JAZZ) Top Compensated Officers

Co-Founder, Executive Chairman and Chief Exec...
Total Annual Compensation: $830.0K
Chief Financial Officer and Executive Vice Pr...
Total Annual Compensation: $402.9K
Chief Operating Officer and Executive Vice Pr...
Total Annual Compensation: $493.5K
Executive Vice President and General Counsel
Total Annual Compensation: $483.5K
Senior Vice President of U.S. Commercial
Total Annual Compensation: $296.2K
Compensation as of Fiscal Year 2014.

jazz pharmaceuticals plc (JAZZ) Key Developments

Jazz Pharmaceuticals Public Limited Company, Jazz Securities Limited, Jazz Pharmaceuticals, Inc., Jazz Financing I Limited, and Jazz Pharmaceuticals Ireland Limited, Enter into A Credit Agreement

On June 18, 2015, Jazz Pharmaceuticals Public Limited Company, (Jazz Pharmaceuticals), Jazz Securities Limited, (the Lead Borrower), Jazz Pharmaceuticals, Inc. (the U.S. Borrower), Jazz Financing I Limited, (Jazz Financing) and Jazz Pharmaceuticals Ireland Limited, (Jazz Ireland and together with the Lead Borrower, the U.S. Borrower and Jazz Financing, the Borrowers and each, a Borrower), entered into a Credit Agreement (the Credit Agreement) with the lenders from time to time party thereto and Bank of America, N.A., as Collateral Agent (in such capacity, the Collateral Agent), Administrative Agent, Swing Line Lender and L/C Issuer. The Credit Agreement provides for (i) a five-year $750 million term loan facility (the Term Loan Facility), which was drawn in full at closing, and (ii) a five-year revolving credit facility of $750 million (the Revolving Credit Facility), of which $160 million was drawn at closing. The Revolving Credit Facility includes a $25 million swing line loan subfacility and a $25 million letter of credit subfacility. The Lead Borrower used the proceeds from initial borrowings under the Credit Agreement to repay loans under that certain Credit Agreement, dated as of June 12, 2012, among the U.S. Borrower, Jazz Pharmaceuticals, certain subsidiaries of Jazz Pharmaceuticals party thereto, the lenders party thereto and Barclays Bank PLC, as administrative agent, collateral agent, letter of credit issuer and swing line lender (the Existing Credit Agreement), and to pay related fees and expenses. The Borrowers expect to use future loans under the Revolving Credit Facility, if any, for general corporate purposes, including potential business development activities. Upon the repayment of loans under the Existing Credit Agreement, the Existing Credit Agreement was terminated. Loans under the Term Loan Facility and Revolving Credit Facility bear interest, at the applicable Borrower's option, at a rate equal to either (a) the LIBOR rate, plus an applicable margin ranging from 1.50% to 2.25% per annum, based upon the secured leverage ratio (as defined in the Credit Agreement), or (b) the prime lending rate, plus an applicable margin ranging from 0.50% to 1.25% per annum, based upon the secured leverage ratio (as defined in the Credit Agreement). The Borrowers' obligations under the Credit Agreement and any hedging or cash management obligations entered into with a lender are guaranteed by Jazz Pharmaceuticals and each of Jazz Pharmaceuticals' existing and subsequently acquired or organized direct and indirect subsidiaries (other than, among other exceptions, certain immaterial subsidiaries, subsidiaries whose guarantee would result in material adverse tax consequences and subsidiaries whose guarantee is prohibited by applicable law). Jazz Pharmaceuticals, the Borrowers and such guarantors are collectively referred to in this Current Report on Form 8-K as the Loan Parties. The Loan Parties' obligations under the Credit Agreement are secured, subject to customary permitted liens and other agreed upon exceptions, by a perfected security interest in (a) all tangible and intangible assets of the Loan Parties, except for certain excluded assets, and (b) all of the equity interests of the subsidiaries of the Loan Parties held by the Loan Parties (limited, in the case of the voting equity interests of certain foreign subsidiaries and certain domestic subsidiaries that hold no assets other than equity interests of foreign subsidiaries, to 65% of the voting equity interests of such subsidiaries).

Jazz Pharmaceuticals Public Limited Company Presents at Cantor Fitzgerald's Inaugural Healthcare Conference, Jul-08-2015 09:30 AM

Jazz Pharmaceuticals Public Limited Company Presents at Cantor Fitzgerald's Inaugural Healthcare Conference, Jul-08-2015 09:30 AM. Venue: Le Parker Meridien Hotel, 119 W. 56th Street, New York, NY 10019, United States. Speakers: Russell J. Cox, Chief Operating Officer and Executive Vice President.

Aytu BioScience, Inc. Acquires the Rights to Prostascint from Jazz Pharmaceuticals plc

Aytu BioScience Inc., has entered into an agreement to acquire the rights to ProstaScint(R), an imaging agent used to detect the extent and spread of prostate cancer that is marketed in the US, from Jazz Pharmaceuticals plc. ProstaScint is a murine monoclonal antibody conjugated to a linker-chelator that targets Prostate Specific Membrane Antigen (PSMA), a glycoprotein expressed by the prostate epithelium. The transaction will enable Aytu to expand its footprint in urology and advance its pipeline of therapeutics and diagnostics.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
JAZZ:US $192.24 USD +1.86

JAZZ Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Akorn Inc $46.11 USD -0.22
Alkermes PLC $70.02 USD +2.49
BioMarin Pharmaceutical Inc $146.27 USD +1.71
Impax Laboratories Inc $48.46 USD +0.10
Incyte Corp $104.28 USD +1.32
View Industry Companies

Industry Analysis


Industry Average

Valuation JAZZ Industry Range
Price/Earnings 55.2x
Price/Sales 9.5x
Price/Book 9.0x
Price/Cash Flow 34.4x
TEV/Sales 7.8x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact JAZZ PHARMACEUTICALS PLC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at